{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Buckler AJ"],"funding":["NHLBI NIH HHS"],"pagination":["1204071"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10435977"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["<h4>Aims</h4>Residual cardiovascular risk persists despite statin therapy. In REDUCE-IT, icosapent ethyl (IPE) reduced total events, but the mechanisms of benefit are not fully understood. EVAPORATE evaluated the effects of IPE on plaque characteristics by coronary computed tomography angiography (CCTA). Given the conclusion that the IPE-treated patients demonstrate that plaque burden decreases has already been published in the primary study analysis, we aimed to demonstrate whether the use of an analytic technique defined and validated in histological terms could extend the primary study in terms of whether such changes could be reliably seen in less time on drug, at the individual (rather than only at the cohort) level, or both, as neither of these were established by the primary study r"],"journal":["Frontiers in cardiovascular medicine"],"pubmed_title":["Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE."],"pmcid":["PMC10435977"],"funding_grant_id":["R01 HL134892"],"pubmed_authors":["Muhlestein JB","Shaikh K","Budoff MJ","Nicolaou A","May HT","Kinninger A","Libby P","Nelson JR","Lakshmanan S","Zheng L","Buckler AJ","Le VT","Shekar C","Tayek JA","Roy SK","Doros G","Bhatt DL"],"additional_accession":[]},"is_claimable":false,"name":"Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE.","description":"<h4>Aims</h4>Residual cardiovascular risk persists despite statin therapy. In REDUCE-IT, icosapent ethyl (IPE) reduced total events, but the mechanisms of benefit are not fully understood. EVAPORATE evaluated the effects of IPE on plaque characteristics by coronary computed tomography angiography (CCTA). Given the conclusion that the IPE-treated patients demonstrate that plaque burden decreases has already been published in the primary study analysis, we aimed to demonstrate whether the use of an analytic technique defined and validated in histological terms could extend the primary study in terms of whether such changes could be reliably seen in less time on drug, at the individual (rather than only at the cohort) level, or both, as neither of these were established by the primary study r","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-26T23:51:54.814Z","creation":"2025-04-06T17:39:25.652Z"},"accession":"S-EPMC10435977","cross_references":{"pubmed":["37600044"],"doi":["10.3389/fcvm.2023.1204071"]}}